Twenty PLX-4720's That's Going To Rock n roll This Present Year

As per RSBY coverage of 3.5 persons per family (10), if we calculate with two Entinostat purchase earning members per family with 1.5 dependant members, the annual income per family per year is expected to be Rs. 10,800 for WB and Rs. 10,200 for MAH. With Rs. 30,000 floating coverage of RSBY, it covers 278% of the annual income of BPL families in WB and 294% of the BPL families in MAH. With morbidity coming as a shock and the treatment part leading to disastrous outcomes in terms of burden leading to medical poverty trap for most of the deserving population. With high potential coverage as proportion of annual income, the potential benefit is very high even if family is taken as unit. This coverage in turns protects the families from the potential medical poverty trap. Considering a combined effect of RSBY and NRTN, the expected net benefit per capita comes to Rs. 5,186 for MAH and Rs. 5,110 for WB for the deserving population. Thus a 10% more spread of the duo would result in Rs. 22.58 billion for MAH and Rs. 22.63 billion for WB for the deserving BPL population alone which is approximately 0.24% and 0.52% of the gross State Domestic Product (SDP) of the respective states. Since NRTN network is for all, the resultant benefit is expected to be more than as estimated. Population density being higher in WB and MAH being spread across larger area, the benefits of telemedicine would expectedly serve MAH more. Though MAH is one of the better performers in India in terms of health infrastructure and health attainment indices and WB is an average performer in these respect, both States will be in a position to benefit largely from the expansion of RSBY as well as NRTN projects Medicines take the major share in treatment cost. Drugs are different from other consumer items. So the free market economy and the price competition cannot make the prices lower for them. Branding in drugs creates artificial monopoly and drug manufacturers are able to keep the MRP higher in spite of presence of competitors in the market. The need for the drugs is always urgent. Consumers of drugs are vulnerable. The branding and high MRP make the situation worse especially for those who come from poor economic background. Table 3 compares the price of some common life saving medicines when sold in generic name and in branded pack. The difference is enormous as revealed from the table. If the drugs are sold through FPS in generic name it would be of immense benefit for the people who avail public healthcare services. The mechanism has been extremely successful in WB. The OOP expenditure of the patient for treatment is 6.15% of the average annual SDP of the state out of which 66% is spent on medicines only (19). FPS was introduced in the state in the end of 2012.